[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Enanta Pharmaceuticals, Inc\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":79},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100634532","phase-1-a-study-to-investigate-the-safety-tolerability-pharmacokinetics-and-pharmacodynamics-of-single-and-multiple-doses-of-edp-978-in-healthy-adults-100634532",false,"NCT07540910","A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of EDP-978 in Healthy Adults","A Randomized, Double-Blind, Sponsor-Open, Placebo-Controlled, First-In-Human, Phase 1 Study of Orally Administered EDP-978 to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses, Multiple Ascending Doses, and the Effect of Food on EDP-978 Pharmacokinetics in Healthy Adult Participants","Inclusion Criteria:\n\n* An informed consent document signed and dated by the subject.\n* Healthy male and female subjects of any ethnic origin between the ages of 18 and 65 years, inclusive.\n\nExclusion Criteria:\n\n* Clinically relevant evidence or history of illness or disease.\n* Infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) at screening and infection with SARS-CoV-2 at the Day -1 visit\n* Pregnant or nursing females.\n* History of febrile illness within 7 days prior to the first dose of study drug or subjects with evidence of active infection.\n* A positive urine drug screen at screening or Day -1.\n* Current tobacco smokers or use of tobacco within 3 months prior to screening.\n* Any condition possibly affecting drug absorption (e.g., gastrectomy, cholecystectomy).\n* History of regular alcohol consumption.\n* Receipt of any vaccine, an investigational agent or biological product within 28 days or 5 times the t½, whichever one is longer, prior to first dose.",true,"ALL","18 Years","65 Years",{"count":21,"type":22},98,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","This study is a randomized, double-blind, sponsor-open, placebo-controlled study. It will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of orally administered single and multiple doses of EDP-978 in healthy adult subjects.",[28,29],"Chronic Inducible Urticaria","Chronic Spontaneous Urticaria",[31,32,33,34],"First-in-Human","Single Ascending Dose","Multiple Ascending Dose","Healthy Participant","RECRUITING","2026-04-17",{"date":38,"type":39},"2026-04-21","ACTUAL",{"date":41,"type":39},"2026-04-01",{"date":43,"type":22},"2026-11",{"name":45,"class":46},"Enanta Pharmaceuticals, Inc","INDUSTRY",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":61,"conditions":62,"keywords":66,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":4},"100630052","phase-2-a-phase-2-study-to-investigate-the-efficacy-and-safety-of-zelicapavir-in-participants-aged-28-days-to-36-months-of-age-infected-with-respiratory-syncytial-virus-100630052","NCT07482657","A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus","Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zelicapavir in Participants ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus","Inclusion Criteria:\n\n* Participants diagnosed with RSV infection using an approved diagnostic assay, without known and\u002For documented coinfection with SARS-CoV-2 or influenza\n* Participant has signs of RSV infection with onset ≤3 days (72 hours) at the time of randomization\n* In the Investigator's opinion, the participant's caregiver understands and is able to comply with protocol requirements, instructions, and restrictions, and the participant is likely to complete the study as planned. The caregiver(s) should be of legal age.\n\nExclusion Criteria:\n\n* Participant has any condition that in the opinion of the Investigator would interfere with the evaluation of the study drug or participant safety.\n* Participant has underlying immune deficiency. Participants with immunoglobulin A deficiency are not excluded.\n* Participant has had major surgery within 6 weeks prior to randomization or has major surgery planned during the course of the study.\n* Participant is currently taking either chronically or has taken within 7 days prior to randomization, or is anticipated to receive during the course of the study, systemic medications that are known to cause immunosuppression other than corticosteroids for \\>5 days.\n* Participant has received an investigational agent within the last 30 days or 5 half-lives of the investigational agent, whichever is longer.","28 Days","36 Months",{"count":58,"type":22},150,[60],"PHASE2","Zelicapavir is a novel, orally administered, nonfusion replication inhibitor of RSV. It is being investigated in this Phase 2 study (EDP 938-203) as a potential treatment for RSV infection in both hospitalized and non-hospitalized children aged ≥28 days to ≤36 months who present with symptomatic RSV infection.",[63,64,65],"RSV Infection","RSV","Respiratory Syncytial Virus (RSV)",[64,67,68,69],"children","Respiratory Syncytial Virus","Pediatric study","NOT_YET_RECRUITING","2026-03-16",{"date":73,"type":39},"2026-03-19",{"date":75,"type":22},"2026-07",{"date":77,"type":22},"2026-12",{"name":45,"class":46},""]